BD (Becton, Dickinson and Company) (NYSE: BDX) announced that its CentroVena One™ Insertion System has received an Innovative Technology contract from Vizient, a healthcare performance improvement company. The contract was awarded following a review by hospital experts on Vizient's client-led councils, according to a press release from BD.

The CentroVena One™ system integrates a guidewire, needle, syringe and catheter into a single unit, which BD describes as the first all-in-one central venous catheter insertion system. The company says the design results in 30% fewer steps and a 50% reduction in maximum procedure time compared to standard techniques, based on a head-to-head simulation study of 49 participants published in The Journal of Emergency Medicine in December 2025.

Traditional central line insertion can involve dozens of steps and multiple component exchanges. BD states the system includes design features intended to reduce contamination risk and lower the likelihood of complications such as air and guidewire embolism, needlestick injury and clinician blood exposure.

"Receiving a Vizient Innovative Technology contract recognizes the innovation behind CentroVena One™ and its potential to redefine how central lines are placed," said Eric Borin, worldwide president of Medication Delivery Solutions at BD.

Kelly Flaharty, associate vice president of contract operations for Vizient, said the council recommended the contract after the product "demonstrated the potential to offer meaningful differentiation."

Vizient's client base includes academic medical centers, community hospitals and integrated health delivery networks, with a purchasing portfolio representing more than $156 billion in annual volume. Through its Innovative Technology Program, Vizient may award contracts outside of the standard competitive bid cycle for products its councils determine to be innovative.